Business Context and Reporting Period
This Form 8-K is a current report filed by Obalon Therapeutics, Inc. (not Vyome Holdings, Inc.) on June 14, 2018. The filing reports on the results of the Company's 2018 Annual Meeting of Stockholders held on June 13, 2018. The registrant is an emerging growth company incorporated in Delaware.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
Stockholders voted on three proposals at the Annual Meeting. The final results were as follows:
- Proposal 1 (Election of Directors): Stockholders elected three Class II Directors (Raymond Dittamore, Les Howe, and David Moatazedi) for a term expiring at the 2021 annual meeting. All three candidates received significant support with over 9.7 million votes "For" each.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2018. The vote was overwhelmingly in favor (14,539,129 For vs. 2,852 Against).
- Proposal 3 (Capital Structure Amendment): Stockholders approved an amendment to the Restated Certificate of Incorporation to reduce the number of authorized common stock shares from 300,000,000 to 100,000,000. The vote was 14,205,936 For, 12,478 Against, and 323,567 Abstentions.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future guidance, outlook, risks, contingencies, or unusual items. It is a procedural report confirming the completion of the annual meeting and the filing of the Certificate of Amendment to the Restated Certificate of Incorporation.
Investor Verification Checklist
- Verify the effective date of the reduction in authorized shares from 300 million to 100 million.
- Confirm the term expiration dates for the newly elected Class II Directors (2021).
- Review the definitive proxy statement (Schedule 14A) filed on April 30, 2018, for detailed background on the proposals.
- Note that this filing does not provide financial performance updates; refer to the most recent 10-K or 10-Q for financial data.